CoChat
Sign Up
Cited by 430Liver Disease and TransplantationGut microbiota and healthGastrointestinal motility and disorders

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

Open access
Bajaj, Jasmohan S., Heuman, Douglas M., Sanyal, Arun J., Hylemon, Phillip B., Sterling, Richard K., Stravitz, R. Todd, Fuchs, Michael, Ridlon, Jason M., Daita, Kalyani, Monteith, Pamela, Noble, Nicole A., White, Melanie B., Fisher, Andmorgan, Sikaroodi, Masoumeh, Rangwala, Huzefa, Gillevet, Patrick M.·2013·PLoS ONE
DOI 10.1371/journal.pone.0060042PMC PMC3615021
Open this paper in CoChat — free accountOpen PDF

Abstract

UNLABELLED: Hepatic encephalopathy (HE) represents a dysfunctional gut-liver-brain axis in cirrhosis which can negatively impact outcomes. This altered gut-brain relationship has been treated using gut-selective antibiotics such as rifaximin, that improve cognitive function in HE, especially its subclinical form, minimal HE (MHE). However, the precise mechanism of the action of rifaximin in MHE is unclear. We hypothesized that modulation of gut microbiota and their end-products by rifaximin would affect the gut-brain axis and improve cognitive performance in cirrhosis. Aim To perform a systems biology analysis of the microbiome, metabolome and cognitive change after rifaximin in MHE. METHODS: Twenty cirrhotics with MHE underwent cognitive testing, endotoxin analysis, urine/serum metabolomics (GC and LC-MS) and fecal microbiome assessment (multi-tagged pyrosequencing) at baseline and 8 weeks post-rifaximin 550 mg BID. Changes in cognition, endotoxin, serum/urine metabolites (and microbiome were analyzed using recommended systems biology techniques. Specifically, correlation networks between microbiota and metabolome were analyzed before and after rifaximin. RESULTS: There was a significant improvement in cognition(six of seven tests improved, p<0.01) and endotoxemia (0.55 to 0.48 Eu/ml, p = 0.02) after rifaximin. There was a significant increase in serum saturated (myristic, caprylic, palmitic, palmitoleic, oleic and eicosanoic) and unsaturated (linoleic, linolenic, gamma-linolenic and arachnidonic) fatty acids post-rifaximin. No significant microbial change apart from a modest decrease in Veillonellaceae and increase in Eubacteriaceae was observed. Rifaximin resulted in a significant reduction in network connectivity and clustering on the correlation networks. The networks centered on Enterobacteriaceae, Porphyromonadaceae and Bacteroidaceae indicated a shift from pathogenic to beneficial metabolite linkages and better cognition while those centered on autochthonous taxa remained similar. CONCLUSIONS: Rifaximin is associated with improved cognitive function and endotoxemia in MHE, which is accompanied by alteration of gut bacterial linkages with metabolites without significant change in microbial abundance. TRIAL REGISTRATION: ClinicalTrials.gov NCT01069133.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0060042

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Consort Flowchart of the Open-label trial.
Figure 1 Consort Flowchart of the Open-label trial.CC BY · PubMed Central
Figure 2 A: Principal Component Analysis of Microbiota. There was no significant change in the PCO of microbiota before and after rifaximin therapy (yellow dots are before and red dots are after rifaximin) B and C: Composition of microbiota families before (figure 2B) and after (figure 2C) rifaximin. There was a significant decrease in Veillonellaceae and increase in Eubacteriaceae abundance after rifaximin therapy (marked in red).
Figure 2 A: Principal Component Analysis of Microbiota. There was no significant change in the PCO of microbiota before and after rifaximin therapy (yellow dots are before and red dots are after rifaximin) B and C: Composition of microbiota families before (figure 2B) and after (figure 2C) rifaximin. There was a significant decrease in Veillonellaceae and increase in Eubacteriaceae abundance after rifaximin therapy (marked in red).CC BY · PubMed Central
Figure 3 Univariate serum metabolomic analysis. There was a significant increase in fatty acids and intermediates of carbohydrate metabolism after rifaximin therapy in the serum.
Figure 3 Univariate serum metabolomic analysis. There was a significant increase in fatty acids and intermediates of carbohydrate metabolism after rifaximin therapy in the serum.CC BY · PubMed Central
Figure 4 Correlation networks before and after rifaximin. Legend common for figures 4A, 4B and 4C: The complex correlation network represented parameters that were linked with a correlation coefficient >0.6 (negative or positive) and with a p value <0.05. Red nodes represent bacterial taxa, green ones the serum metabolites, yellow nodes indicate urinary metabolites while blue ones indicate clinical parameters. Red edges represent negative correlation between connected nodes and blue edges indicate positive correlations. A: Correlation network before rifaximin (BCN) with r>0.6 or <−0.6 and p<0.001. B: Correlation network after rifaximin (ACN) with r>0.6 or <−0.6 and p<0.001. C: is the intersection of 5A and B. It demonstrates those nodes and correlations that remain exactly same before and after rifaximin. D: Cumulative Degree Function curve. This graph plots the cumulative degree function of the node frequency distributions before and after rifaximin. It shows that after rifaximin therapy there was a significant reduction in network complexity (p<0.0001). Blue line: before and red line: after rifaximin. E: Correlation difference before and after rifaximin. This figure shows the correlations that significantly changed between the before and after rifaximin state; i.e. if two nodes were connected positively in the before rifaximin network but aftr rifaximin changed to negative, they are represented here. While the color coding of the nodes is similar, red edges demonstrate linkages that were positive in the BCN but became negative in ACN, while blue edges represent correlations that changed from negative to positive after the use of rifaximin.
Figure 4 Correlation networks before and after rifaximin. Legend common for figures 4A, 4B and 4C: The complex correlation network represented parameters that were linked with a correlation coefficient >0.6 (negative or positive) and with a p value <0.05. Red nodes represent bacterial taxa, green ones the serum metabolites, yellow nodes indicate urinary metabolites while blue ones indicate clinical parameters. Red edges represent negative correlation between connected nodes and blue edges indicate positive correlations. A: Correlation network before rifaximin (BCN) with r>0.6 or <−0.6 and p<0.001. B: Correlation network after rifaximin (ACN) with r>0.6 or <−0.6 and p<0.001. C: is the intersection of 5A and B. It demonstrates those nodes and correlations that remain exactly same before and after rifaximin. D: Cumulative Degree Function curve. This graph plots the cumulative degree function of the node frequency distributions before and after rifaximin. It shows that after rifaximin therapy there was a significant reduction in network complexity (p<0.0001). Blue line: before and red line: after rifaximin. E: Correlation difference before and after rifaximin. This figure shows the correlations that significantly changed between the before and after rifaximin state; i.e. if two nodes were connected positively in the before rifaximin network but aftr rifaximin changed to negative, they are represented here. While the color coding of the nodes is similar, red edges demonstrate linkages that were positive in the BCN but became negative in ACN, while blue edges represent correlations that changed from negative to positive after the use of rifaximin.CC BY · PubMed Central
Figure 5 Subset of correlation differences before and after rifaximin. This figure is limited to the metabolomics and clinical/cognitive features that changed with rifaximin and their interaction with the bacterial taxa. The linkages that significantly changed in nature (positive to negative or vice-versa) or intensity (less to more or vice-versa while remaining positive or negative) with p<0.05 are shown. Nodes: Blue: bacterial taxa, green: serum metabolites, Yellow: cognitive or clinical data. Linkages were dark blue if correlations were positive before and changed significantly to negative, light blue if they changed significantly but remained positive throughout, red if correlations were negative at baseline but changed to positive after therapy and green is negative relationship throughout but a significant change.
Figure 5 Subset of correlation differences before and after rifaximin. This figure is limited to the metabolomics and clinical/cognitive features that changed with rifaximin and their interaction with the bacterial taxa. The linkages that significantly changed in nature (positive to negative or vice-versa) or intensity (less to more or vice-versa while remaining positive or negative) with p<0.05 are shown. Nodes: Blue: bacterial taxa, green: serum metabolites, Yellow: cognitive or clinical data. Linkages were dark blue if correlations were positive before and changed significantly to negative, light blue if they changed significantly but remained positive throughout, red if correlations were negative at baseline but changed to positive after therapy and green is negative relationship throughout but a significant change.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 430

Related

See all

Metadata

Authors
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., Noble, N. A., White, M. B., Fisher, A., Sikaroodi, M., Rangwala, H., & Gillevet, P. M.
Affiliations
  • Virginia Commonwealth University (US)
  • George Mason University (US)
Corresponding author
Bajaj, Jasmohan S.
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-04-02
Volume
8
Issue
4
Pages
e60042
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0060042
PMC
PMC3615021
OpenAlex
W2138196119
Cited by
430
References
46
Citations by year
2026: 19 · 2025: 27 · 2024: 34 · 2023: 34 · 2022: 25 · 2021: 40 · 2020: 31 · 2019: 37 · 2018: 45 · 2017: 27 · 2016: 31 · 2015: 43 · 2014: 25 · 2013: 9
FWCI
22.45
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • VCU Scholars Compass (Virginia Commonwealth University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health (UL1TR000058)
  • University of California, Davis
  • National Institute on Alcohol Abuse and Alcoholism (R01AA020203, RO1AA020203)
  • National Institute of Diabetes and Digestive and Kidney Diseases (RO1AA020203, RO1DK087913, R01DK087913)
  • National Center for Complementary and Alternative Medicine (RO1AA020203)
  • National Center for Advancing Translational Sciences
  • National Center for Complementary and Integrative Health (U01AT004428)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
rifaximin, minimal hepatic encephalopathy, liver cirrhosis, gut microbiota, gut-brain axis, endotoxemia, cognitive function, serum metabolomics, urine metabolomics, fatty acids, Veillonellaceae, Enterobacteriaceae, Bacteroidaceae, Porphyromonadaceae
MeSH terms
Rifaximin, Cognition, Female, Hepatic Encephalopathy, Humans, Liver Cirrhosis, Male, Middle Aged, Rifamycins, Gastrointestinal Tract, Metagenome, Metabolomics, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review